Objective
to investigate if extended P2Y12 inhibitor monotherapy is better than ongoing DAPT (aspirin + clopidogrel) after 9 to 12 months of DAPT after PCI
Study
multicentre, double-blind, placebo controlled randomised trial
Population
patients at high risk of bleeding and ischaemia with ACS
Endpoints
BARC types 2, 3, or 5 at 9 months after randomisation
/medias/8742/25-T009_Li_02.jpg)
/medias/8745/25-T009_Li_01.jpg)
Conclusion
an extended 9-month clopidogrel monotherapy was better than continuous DAPT in patients with high bleeding and ischaemic risk after PCI for ACS and DAPT for 9 to 12 months
Li et al. JAMA Cardiol. 2024;9:523-531